Highlights of the Peptide Industry Summit | Haipu New Materials Showcases at Peptides 2026

The 3rd Peptides 2026 Peptide Drug Industry Innovation Summit, a two-day event, successfully concluded in Suzhou on March 5th and 6th. As a core material supplier in the upstream of the peptide industry chain, Haipu New Materials showcased its peptide solid-phase synthesis carriers, separation and purification packing materials, microporous filtration membranes, and overall separation and purification solutions at booth A10. The company engaged in in-depth exchanges with hundreds of industry peers, directly addressing real challenges in R&D and production, and exploring feasible technological pathways.

The two-day exhibition was a convergence of technological consensus and a concentrated burst of cooperation opportunities.

01 More than just "products," it's about "solutions"—focusing on the entire peptide drug development process, Haipu showcases its complete product matrix.

At this exhibition, Haipu focused on the core needs of peptide drug research and development and production, showcasing core products for the entire synthesis-purification process and providing customized material solutions for different application scenarios, becoming the focus of the event!

Peptide solid-phase synthesis carrier

To address the challenges in synthesizing long-chain peptides such as GLP-1, Haipu showcased a variety of carrier products, including Rink Amide-AM resin, Rink Amide-MBHA resin, Sieber resin, 2-CTC resin, and Wang resin.

Leveraging a rigorous quality control system, this series of resins achieves high-precision control of substitution degree ±0.01 mmol/g and swelling degree ±0.2 mL/g, ensuring stable and reliable results for each batch. Simultaneously, thanks to its excellent product purity and chemical stability, it significantly reduces synthetic byproducts, helping customers achieve higher synthesis yields. Different resins have different focuses in terms of substitution degree, swelling properties, and pyrolysis conditions, meeting diverse synthetic needs from short peptides to long-chain polypeptides, and from peptide acids to peptide amides. Currently, this series of products has achieved stable supply at a scale of hundreds of kilograms, with annual production capacity fully covering the needs of the entire process from R&D to commercial production.

Separation and purification packing

The efficiency of the purification process directly impacts the production cost of peptide drugs. Haipu's C18 series packing materials are optimized for peptide molecular characteristics: different pore sizes are designed to match different peptide chain lengths, and surface modifications reduce non-specific adsorption, improving yield while ensuring purity. The performance of Haipu's C18 packing materials in terms of loading capacity, lifetime, and batch stability became a key focus for many visitors.

Microporous Filtration Membranes

In addition to synthesis and purification products, Haipu also showcased its microporous filtration membrane product line. This series of membrane materials has wide applications in biopharmaceutical filtration processes, meeting the needs of various scenarios such as feed clarification and sterilization filtration. It works synergistically with synthesis and purification products to achieve more comprehensive coverage of downstream biopharmaceutical processes.

02 More Than Just a Showcase, It Was an In-Depth Dialogue

The Haipu booth was consistently bustling with visitors, attracting numerous industry experts and company representatives to stop and exchange ideas. Haipu's technical team engaged in in-depth discussions with visiting guests on practical issues such as synthesis yield, purification efficiency, and process scale-up, creating a lively atmosphere.

03 From "Single-Point Product" to "Complete Chain": Building a Complete Technology Closed Loop

In the research and development and production of peptide drugs, synthetic carriers and purification fillers are often provided by different suppliers. The smoothness of process integration is currently a crucial direction for process optimization.

Haipu's simultaneous development of both synthesis and purification product lines aims to provide customers with more coherent technical support: from the selection of carriers for solid-phase synthesis to the development of reverse-phase purification methods, the coordination between the two stages is more controllable. The addition of microporous filtration membranes further extends Haipu's service capabilities in downstream biopharmaceutical processes. This complete "synthesis + purification" chain won unanimous praise from the attendees.

Haipu firmly believes that materials innovation is the core driving force for the development of the biopharmaceutical industry. From the basic carriers for peptide solid-phase synthesis to key fillers and membrane materials in the purification process, and then to the overall industrial separation and purification solutions, we adhere to a customer-centric approach, using stable product quality, feasible solutions, and full-process technical services to help the peptide industry move towards a more efficient and controllable future.

The conclusion of Peptides 2026 marks not only the end of one exchange but also the beginning of many more collaborations. Moving forward, Hypu will continue to focus on materials innovation, continuously optimizing its peptide synthesis and purification solutions, and working hand-in-hand with colleagues in the peptide industry to overcome technological bottlenecks and create a new chapter in the industry's success on this golden track!